10-Q: Q2 2024 Earnings Report
Dermata Therapeutics Entred Agreements For The Immediate Exercise Of Certain Warrants To Purchase Up To An Aggregate Of 516,336 Shares Of The Co's Common Stock, Having Exercise Prices Of $9.7665 And $32.40 Per Share
Express News | Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times
10-Q: Q1 2024 Earnings Report
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now